The board of directors Merck (NYSE:MRK) authorised a dividend of USD0.65 per share of the company's common stock for the third quarter of 2021, it declared on Tuesday.
This dividend is payable on 7 July 2021 to shareholders of record at the close of business as of 15 June 2021.
According to the biopharmaceutical company, it has been bringing forward medicines and vaccines for many of the world's most challenging diseases and is at the forefront of research to prevent and treat diseases including cancer, HIV and Ebola.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer